No link found between patient genetics and response to anti-IL17 therapy
4 September 2023
A new study looked at the effect of patient genetics on their response to secukinumab, an anti-IL17 therapy commonly used to treat inflammatory conditions including arthritis and psoriasis. No link was found between a patient’s genetic variants and their response to therapy. This study challenges the idea that genetics might significantly account for the variable responses to anti-IL17 therapy seen in the clinic.
EPSRC fellowship awarded to Huw Colin-York
4 July 2023
Huw Colin-York has been awarded a fellowship from the Engineering and Physical Sciences Research Council (EPSRC) to develop synthetic biology tools to understand the immune response.
Newly discovered cells could be responsible for atherosclerosis complications
27 June 2023
A new type of macrophages recently identified in atherosclerotic lesions could provide a missing link in understanding the inflammatory origins of the common yet fatal condition.
Michael Dustin joins strategic research collaboration with EvolveImmune Therapeutics
15 June 2023
The research will use the Kennedy’s state-of-the-art technology to understand the effect of EVOLVE molecules in the immune response to tumours.
Mitochondrial protein synthesis identified as a potential therapeutic target in lymphoma
1 June 2023
A team led by Alex Clarke at the Kennedy Institute has identified how high mitochondrial activity regulates antibody responses crucial for immunity but is also necessary for the development of lymphoma.
Shifting the dogma about synovial lining macrophages: the early drivers of rheumatoid arthritis
24 May 2023
Insights into a specific macrophage population suggest that these cells could drive inflammation in rheumatoid arthritis. Understanding their complex role could lead to better treatments for patients.
New partnership will accelerate AI-driven immunotherapies
17 May 2023
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies
Professor Michael Dustin elected to the Royal Society
10 May 2023
The Kennedy professor is one of eight researchers from Oxford University who received a prestigious fellowship from the Royal Society in recognition of their work in the fields of science and medicine.
New hope for patients after vedolizumab found effective to treat Chronic Pouchitis
31 March 2023
A new study led by Oxford researchers has found vedolizumab can induce remission in patients who have chronic pouchitis after surgery for ulcerative colitis.
New approach to nail bed injury surgery could significantly cut NHS costs
30 March 2023
According to a new Oxford study, changing clinical practice for finger injuries in children could save the NHS £720,000 per year.
Fat tissues can play a protective role against inflammation in the intestine
22 February 2023
A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.
Kennedy researchers awarded Sir Henry Wellcome Fellowships
16 February 2023
Kennedy Institute researchers Mariana Borsa and Edward Jenkins have both been awarded Sir Henry Wellcome Postdoctoral Fellowships, which give recently qualified postdoctoral researchers the opportunity to start independent research careers.
Communication at the crossroads of the immune system
6 February 2023
In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.
The Kennedy Institute launches its single cell facility
4 January 2023
We spoke to Irina Udalova and Stephen Sansom about the Kennedy’s new single cell facility and how it will enhance research at the Institute and beyond.
New drug offers hope for people with hand osteoarthritis
22 December 2022
A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.
Professor Michael Dustin appointed new Chair in Molecular Immunology
6 December 2022
A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.
Two prestigious Hunterian Professorships awarded to NDORMS researchers
1 December 2022
Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England
Dr Alex Clarke wins Emerging Leaders Prize for lupus research
30 November 2022
Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.
The Kennedy’s research strongly endorsed following independent review
29 November 2022
We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.
A new research computing platform advances the understanding of key biological processes in disease
22 November 2022
To respond to advances in technology and try to answer an increasing range of biological questions, the Kennedy Institute has invested in a high-performance computing facility. We speak to Brian Marsden, Associate Professor of Research Informatics at the Kennedy to find out more.